Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

IF 1.8 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Visceral Medicine Pub Date : 2022-02-01 DOI:10.1159/000519754

Henrik Nienhüser, Markus W Büchler, Martin Schneider

{"title":"Resection of Recurrent Pancreatic Cancer: Who Can Benefit?","authors":"Henrik Nienhüser, Markus W Büchler, Martin Schneider","doi":"10.1159/000519754","DOIUrl":null,"url":null,"abstract":"Background: Recurrence after resection of pancreatic cancer occurs in up to 80% of patients in the first 2 years after complete resection. While most patients are not eligible for surgical treatment due to disseminated disease, a certain group of patients can be evaluated for re-resection of local recurrence. This review summarizes the current literature on surgical treatment of recurrent pancreatic cancer and potential prognostic factors.Summary: Re-resection of recurrent pancreatic cancer provides a significant survival benefit to selected patients with acceptable procedure-related mortality. Median overall survival after re-resection of recurrent pancreatic cancer is up to 28 months. The most relevant clinical parameters associated with a prognostic benefit are young patient age (<65 years), time to initial resection (>10 months), and preoperative chemotherapy before re-resection. Molecular markers are currently under investigation and might help to improve patient selection in the future.Key message: Re-resection of recurrent pancreatic cancer is safe and feasible in experienced hands. Selected patients benefit from surgical treatment, but future studies are needed to identify reliable prognostic markers predicting survival.","PeriodicalId":56003,"journal":{"name":"Visceral Medicine","volume":"38 1","pages":"42-48"},"PeriodicalIF":1.8000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874245/pdf/vis-0038-0042.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Visceral Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000519754","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Recurrence after resection of pancreatic cancer occurs in up to 80% of patients in the first 2 years after complete resection. While most patients are not eligible for surgical treatment due to disseminated disease, a certain group of patients can be evaluated for re-resection of local recurrence. This review summarizes the current literature on surgical treatment of recurrent pancreatic cancer and potential prognostic factors.

Summary: Re-resection of recurrent pancreatic cancer provides a significant survival benefit to selected patients with acceptable procedure-related mortality. Median overall survival after re-resection of recurrent pancreatic cancer is up to 28 months. The most relevant clinical parameters associated with a prognostic benefit are young patient age (<65 years), time to initial resection (>10 months), and preoperative chemotherapy before re-resection. Molecular markers are currently under investigation and might help to improve patient selection in the future.

Key message: Re-resection of recurrent pancreatic cancer is safe and feasible in experienced hands. Selected patients benefit from surgical treatment, but future studies are needed to identify reliable prognostic markers predicting survival.

查看原文本刊更多论文

复发性胰腺癌切除术:谁会受益?

背景:胰腺癌切除术后复发发生率高达80%的患者在完全切除后的头2年。虽然大多数患者因疾病播散不适合手术治疗，但有一部分患者可以评估局部复发再切除。本文综述了目前关于复发性胰腺癌手术治疗及潜在预后因素的文献。总结:对于手术相关死亡率可接受的复发性胰腺癌患者，再切除提供了显著的生存益处。复发胰腺癌再切除后的中位总生存期可达28个月。与预后获益最相关的临床参数是患者年龄小(10个月)和再切除前的术前化疗。分子标记目前正在研究中，将来可能有助于改善患者的选择。关键信息:复发性胰腺癌再切除术在经验丰富的患者中是安全可行的。选定的患者从手术治疗中获益，但未来的研究需要确定预测生存的可靠预后标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Visceral Medicine Medicine-Surgery

CiteScore

4.50

自引率

0.00%

发文量

期刊介绍： This interdisciplinary journal is unique in its field as it covers the principles of both gastrointestinal medicine and surgery required for treating abdominal diseases. In each issue invited reviews provide a comprehensive overview of one selected topic. Thus, a sound background of the state of the art in clinical practice and research is provided. A panel of specialists in gastroenterology, surgery, radiology, and pathology discusses different approaches to diagnosis and treatment of the topic covered in the respective issue. Original articles, case reports, and commentaries make for further interesting reading.